JP2012514044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514044A5 JP2012514044A5 JP2011544601A JP2011544601A JP2012514044A5 JP 2012514044 A5 JP2012514044 A5 JP 2012514044A5 JP 2011544601 A JP2011544601 A JP 2011544601A JP 2011544601 A JP2011544601 A JP 2011544601A JP 2012514044 A5 JP2012514044 A5 JP 2012514044A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- nitrogen
- sulfur
- oxygen
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 186
- 229910052757 nitrogen Inorganic materials 0.000 claims description 133
- 229910052760 oxygen Inorganic materials 0.000 claims description 108
- 150000001875 compounds Chemical class 0.000 claims description 105
- 229910052717 sulfur Inorganic materials 0.000 claims description 105
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 102
- 239000001301 oxygen Substances 0.000 claims description 102
- 125000005842 heteroatom Chemical group 0.000 claims description 101
- 239000011593 sulfur Substances 0.000 claims description 99
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 97
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 72
- 229920006395 saturated elastomer Polymers 0.000 claims description 62
- 125000005843 halogen group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000004429 atom Chemical group 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000002619 bicyclic group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- -1 imidazolidyl Chemical group 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 208000019838 Blood disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 230000002584 immunomodulator Effects 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 150000003464 sulfur compounds Chemical group 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000020446 Cardiac disease Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000013610 patient sample Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000005550 pyrazinylene group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000005557 thiazolylene group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 0 *N(*)C(C=C1C=CC=CC=C1)=* Chemical compound *N(*)C(C=C1C=CC=CC=C1)=* 0.000 description 60
- 238000000034 method Methods 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N NC1CCCCCC1 Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14156108P | 2008-12-30 | 2008-12-30 | |
| US61/141,561 | 2008-12-30 | ||
| PCT/US2009/069795 WO2010078408A1 (en) | 2008-12-30 | 2009-12-30 | Heteroaryl compounds useful as raf kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012514044A JP2012514044A (ja) | 2012-06-21 |
| JP2012514044A5 true JP2012514044A5 (enExample) | 2013-02-21 |
Family
ID=41719139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011544601A Withdrawn JP2012514044A (ja) | 2008-12-30 | 2009-12-30 | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120040951A1 (enExample) |
| EP (1) | EP2379513A1 (enExample) |
| JP (1) | JP2012514044A (enExample) |
| CN (1) | CN102361859A (enExample) |
| AU (1) | AU2009334997A1 (enExample) |
| CA (1) | CA2748274A1 (enExample) |
| IL (1) | IL213601A0 (enExample) |
| MX (1) | MX2011006997A (enExample) |
| WO (1) | WO2010078408A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| NZ582349A (en) | 2007-06-29 | 2012-06-29 | Sunesis Pharmaceuticals Inc | Heterocyclic compounds useful as raf kinase inhibitors |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| BR112012006239A2 (pt) * | 2009-10-12 | 2015-09-08 | Bayer Cropscience Ag | amidas e tioamidas enquanto agentes pesticidas |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| AU2011313853A1 (en) * | 2010-10-11 | 2013-05-02 | Auckland Uniservices Limited | Substituted benzamides and their uses |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| WO2012166463A2 (en) | 2011-05-27 | 2012-12-06 | Neosome Life Sciences, LLC | Aminooxazole inhibitors of cyclin dependent kinases |
| CN102924444B (zh) | 2011-08-11 | 2015-07-08 | 上海吉铠医药科技有限公司 | Pim激酶抑制剂及其制备方法与在制药中的应用 |
| US9453003B2 (en) | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| US9452995B2 (en) | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| US9458151B2 (en) | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| SG11201406518XA (en) | 2012-04-12 | 2014-11-27 | Univ Leland Stanford Junior | Substituted benzamides and their uses |
| CN104870454B (zh) * | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| AU2014312245B2 (en) * | 2013-08-28 | 2018-12-13 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| JP2017537912A (ja) | 2014-12-02 | 2017-12-21 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての二環式化合物 |
| EP4074378A1 (en) | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EA039916B1 (ru) * | 2015-10-23 | 2022-03-28 | Вифор (Интернациональ) Аг | Новые ингибиторы ферропортина |
| SG10202005377VA (en) * | 2015-10-23 | 2020-07-29 | Vifor Int Ag | Novel ferroportin inhibitors |
| EA201990043A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Антибактериальные соединения |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
| ES3053505T3 (en) * | 2017-03-23 | 2026-01-22 | Clavius Pharmaceuticals Llc | Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| US12077548B2 (en) | 2018-08-22 | 2024-09-03 | Clavius Pharmaceuticals, LLC. | Substituted imidazoles for the inhibition of TGF-β and methods of treatment |
| AR118826A1 (es) | 2019-05-03 | 2021-11-03 | Kinnate Biopharma Inc | Inhibidores de cinasas raf |
| BR112022007612A2 (pt) * | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN112535793B (zh) * | 2020-11-19 | 2021-10-08 | 融冲(深圳)生物医疗科技有限责任公司 | 药物涂层球囊导管的制备方法与应用 |
| EP4326256A4 (en) | 2021-04-23 | 2025-03-19 | Pierre Fabre Medicament | Treating cancer with a RAF inhibition |
| CN117143095A (zh) * | 2023-08-03 | 2023-12-01 | 苏州汉德创宏生化科技有限公司 | 一种6-溴吡唑并[1,5-a]吡啶-3-羧酸及其制备方法 |
| CN117567388B (zh) * | 2023-11-14 | 2024-04-16 | 济南悟通生物科技有限公司 | 一种2-乙酰基-5-噻唑甲酸的合成方法 |
| CN119241530B (zh) * | 2024-09-20 | 2026-04-10 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的药物合成工艺 |
| CN119241529B (zh) * | 2024-09-20 | 2026-04-10 | 武汉九州钰民医药科技有限公司 | 一种Tovorafenib的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP2003073357A (ja) | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するＲｈｏキナーゼ阻害剤 |
| WO2004028526A1 (ja) * | 2002-09-25 | 2004-04-08 | Santen Pharmaceutical Co., Ltd. | ベンズアミド誘導体を有効成分とするリウマチ治療剤 |
| EP1828186A1 (en) * | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| NZ582349A (en) * | 2007-06-29 | 2012-06-29 | Sunesis Pharmaceuticals Inc | Heterocyclic compounds useful as raf kinase inhibitors |
-
2009
- 2009-12-30 EP EP09795675A patent/EP2379513A1/en not_active Withdrawn
- 2009-12-30 AU AU2009334997A patent/AU2009334997A1/en not_active Abandoned
- 2009-12-30 CN CN2009801577085A patent/CN102361859A/zh active Pending
- 2009-12-30 CA CA2748274A patent/CA2748274A1/en not_active Abandoned
- 2009-12-30 MX MX2011006997A patent/MX2011006997A/es not_active Application Discontinuation
- 2009-12-30 WO PCT/US2009/069795 patent/WO2010078408A1/en not_active Ceased
- 2009-12-30 JP JP2011544601A patent/JP2012514044A/ja not_active Withdrawn
- 2009-12-30 US US13/142,603 patent/US20120040951A1/en not_active Abandoned
-
2011
- 2011-06-16 IL IL213601A patent/IL213601A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10766914B2 (en) | DNA alkylating agents | |
| US11787801B2 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
| KR102540515B1 (ko) | 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법 | |
| JP5019884B2 (ja) | 炎症プロセスおよび転移プロセスの調節 | |
| JP6873145B2 (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| JP2010532380A5 (enExample) | ||
| US7767665B2 (en) | 1,3-benzothiazinone derivatives and use thereof | |
| JP2010532381A5 (enExample) | ||
| JP2006523202A (ja) | 生体還元により活性化されるプロドラッグ | |
| JP2008513498A5 (enExample) | ||
| CN110092775B (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
| US12168659B2 (en) | Thioamide derivative and preparation method and application thereof | |
| JPS63500453A (ja) | 双性イオン性二環式化合物およびその塩、溶媒和物、水和物ならびにエステル | |
| JP2009503060A (ja) | Ｎ−フェニル−２−ピリミジン−アミン誘導体及びそれの調製のための工程 | |
| WO2020047518A1 (en) | Ire1 kinase inhibitors and uses thereof | |
| TWI323658B (en) | Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same | |
| JP2010510216A5 (enExample) | ||
| US8952002B2 (en) | Aminoheteroaryl compounds and preparation method and use thereof | |
| JP6689887B2 (ja) | 新規アミドヘテロアリールアロイルヒドラジドエチン | |
| JP2024519668A5 (enExample) | ||
| CN114685429A (zh) | 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用 | |
| CN112625025B (zh) | 吡啶基取代的喹啉类衍生物及其制备方法和用途 | |
| CN111138422B (zh) | 一种用于防治红斑狼疮的药物及其制备方法 | |
| CN106946851B (zh) | 一种用于预防和治疗肾结石的药物 | |
| WO2025166286A1 (en) | Compositions and methods for treating cancer and reducing wnt mediated effects |